Tailored Life Science Insurance

In the life sciences industry, innovation does not stop at the lab bench—it extends across the entire supply chain. As companies develop increasingly complex and sensitive products such as biologics, vaccines, and cell and gene therapies, the challenge of safely transporting these high-value assets has never been more critical. The journey from manufacturing site to end-user is fraught with risk, and even a minor disruption can result in significant financial loss, regulatory complications, and—most importantly—threats to patient safety.

Not long ago, tariff classification and associated payments were accepted as the cost of doing business. Trade professionals have long navigated free trade agreements, customs codes, and supply chain disruptions—often without specialized tools. But today’s global economy demands more.

Through the month of June and into the week of July 4th, 2025, national attention was largely focused on a sweeping federal spending bill moving through Congress as part of the budget reconciliation process. But while media and public attention was centered on healthcare and social welfare funding, most Americans were not aware that the bill also briefly included a contentious litigation finance tax proposal.